28 Liberty Street
39th Floor
New York, NY 10005
United States
646 305 6387
https://beyondspringpharma.com
Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 73
Name | Title | Pay | Exercised | Year born |
---|---|---|---|---|
Dr. Lan Huang Ph.D. | Co-Founder, Chairman & CEO | N/A | N/A | 1971 |
Stephen Kilmer | Head of Investor Relations | N/A | N/A | N/A |
Mr. Gregg Russo | Senior Vice President of Human Resources | N/A | N/A | N/A |
BeyondSpring Inc., a clinical stage biopharmaceutical company, together with its subsidiaries, focuses on the development of cancer therapies. The company's lead asset is the Plinabulin, a selective immune-modulating microtubule-binding agent that has completed Phase III clinical trials for the prevention of chemotherapy-induced neutropenia; and for treatment of later-stage non-small cell lung cancer. It is also developing Plinabulin in combination with various immuno-oncology agents, including nivolumab, a PD-1 antibody for the treatment of non-small cell lung cancer; ipilimumab, a CTLA-4 antibody for the treatment of extensive-stage small cell lung cancer; and in combination with PD-1 or PD-L1 antibodies and radiation for the treatment of various cancers. In addition, the company engages in the development of three small molecule immune agents in preclinical stages; and a drug development platform. The company was founded in 2010 and is headquartered in New York, New York.
BeyondSpring Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.